Premium
The durability of virological success of tenofovir and didanosine dosed at either 400 or 250 mg once daily
Author(s) -
Tung MY,
Mandalia S,
Bower M,
Gazzard B,
Nelson M
Publication year - 2005
Publication title -
hiv medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.53
H-Index - 79
eISSN - 1468-1293
pISSN - 1464-2662
DOI - 10.1111/j.1468-1293.2005.00279.x
Subject(s) - didanosine , medicine , tenofovir , pharmacology , antiretroviral therapy , toxicity , human immunodeficiency virus (hiv) , viral load , virology
Tenofovir (TDF) co‐administered with didanosine (ddI) 400 mg increases ddI plasma concentrations by up to 60%, raising concerns over toxicity. To limit this interaction, the dosage of ddI may be reduced to 250 mg once daily when co‐prescribed with TDF. In this clinical cohort, highly active antiretroviral therapy regimens containing TDF and ddI 250 mg were significantly better tolerated than combinations with TDF and ddI at a dose of 400 mg. Low‐dose ddI 250 mg once daily plus TDF as part of antiretroviral therapy was effective.